• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Harrow Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/20/25 6:01:59 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HROW alert in real time by email
    false 0001360214 0001360214 2025-06-18 2025-06-18 0001360214 us-gaap:CommonStockMember 2025-06-18 2025-06-18 0001360214 HROW:SixTwoFiveSeniorNotesDue2026Member 2025-06-18 2025-06-18 0001360214 HROW:ElevenPointEightSevenFiveSeniorNotesDue2027Member 2025-06-18 2025-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 18, 2025

     

    HARROW, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-35814   45-0567010

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    1A Burton Hills Blvd., Suite 200    
    Nashville, Tennessee   37215
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (615) 733-4730

     

    Not Applicable

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of exchange on which registered
    Common Stock, $0.001 par value per share   HROW   The Nasdaq Stock Market LLC
    8.625% Senior Notes due 2026   HROWL   The Nasdaq Stock Market LLC
    11.875% Senior Notes due 2027   HROWM   The Nasdaq Stock Market LLC

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Act of 1934: Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     
     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    On June 18, 2025, the Company held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The number of shares of common stock entitled to vote at the Annual Meeting was 36,685,171. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 31,271,714. All matters submitted to a binding vote of stockholders at the Annual Meeting were approved. The number of votes cast for and against, and the number of abstentions and broker non-votes with respect to the matters voted upon at the Annual Meeting, are set forth below:

     

    Proposal 1: Election of Directors

     

    Stockholders voted to elect to the Board of Directors the four (4) director nominees named in the Company’s proxy statement to serve until the 2026 annual meeting of stockholders or until their successors are duly elected and qualified. The results of the voting were:

     

    Directors  For  Withheld  Broker Non-Vote
    Mark L. Baum  23,643,847  272,563  7,355,304
    Adrienne L. Graves  23,200,214  716,196  7,355,304
    Lauren P. Silvernail  23,624,033  292,377  7,355,304
    Perry J. Sternberg  23,616,257  300,153  7,355,304

     

    Proposal 2: Approval of the Harrow, Inc. 2025 Incentive Stock and Awards Plan

     

    Stockholders voted to approve the Harrow, Inc. 2025 Incentive Stock and Awards Plan. The results of the voting were:

     

    For  Against  Abstain  Broker Non-Vote
    21,700,605  1,773,539  442,266  7,355,304

     

    Proposal 3: Ratification of Auditors

     

    Stockholders ratified the selection of Crowe LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The results of the voting were:

     

    For  Against  Abstain  Broker Non-Vote
    31,229,548  23,282  18,884  -

     

    Proposal 4: To approve on a non-binding, advisory basis, the compensation of the Company’s named executive officers.

     

    Stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers. The results of the voting were:

     

    For  Against  Abstain  Broker Non-Vote
    22,496,427  971,206  448,777  7,355,304

     

    Proposal 5: To approve on a non-binding, advisory basis, the frequency of a stockholder advisory vote on the compensation of the Company’s named executive officers.

     

    Stockholders approved, on a non-binding, advisory basis, a frequency of one year for a stockholder advisory vote on the compensation of the Company’s named executive officers. The results of the voting were:

     

    One Year  Two Years  Three Years  Abstain  Broker Non-Vote
    20,415,407  7,346  2,868,210  625,447  7,355,304

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      HARROW, INC.
         
    Dated: June 20, 2025 By: /s/ Andrew R. Boll
        Andrew R. Boll
        Chief Financial Officer

     

     

     

     

    Get the next $HROW alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HROW

    DatePrice TargetRatingAnalyst
    7/11/2025$76.00Overweight
    Cantor Fitzgerald
    6/12/2025$62.00Buy
    BTIG Research
    6/10/2025Outperform
    William Blair
    2/6/2025$57.00Buy
    H.C. Wainwright
    12/4/2024$73.00 → $69.00Buy
    B. Riley Securities
    4/11/2024$24.00Buy
    Craig Hallum
    9/8/2022$17.00Buy
    B. Riley Securities
    10/14/2021$16.00Buy
    B. Riley Securities
    More analyst ratings

    $HROW
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

      Harrow to assume full commercial responsibility for BYOOVIZ® and OPUVIZ™ by the end of 2025 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a definitive agreement with Samsung Bioepis Co. Ltd. (hereafter "Samsung Bioepis") to secure the exclusive U.S. commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis — BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTISi (ranibizumab), and OPUVIZ™ (aflibercept-yszy), an FDA-approved biosimilar referencing EYLEAii (aflibercept) — two of the most widely used anti-VEGF therapies for retinal diseases. BYOOVIZ has been commercialized

      7/17/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

      Harrow will assume full commercial responsibility for BYOOVIZ® (ranibizumab-nuna) and OPUVIZ™ (aflibercept-yszy) upon full transition of Biogen's commercialization rights back to Samsung Bioepis by the end of 2025 BYOOVIZ, approved by the FDA in September 2021 as the first ophthalmology biosimilar in the US, has been commercially available since June 2022 OPUVIZ was approved by the FDA in May 2024 Samsung Bioepis Co., Ltd. ("Samsung Bioepis") announced today that the company has entered into a license, development and commercialization agreement (DCA) with Harrow (NASDAQ:HROW), for Samsung Bioepis' ophthalmology portfolio — BYOOVIZ® (ranibizumab-nuna), a biosimilar referencing LUC

      7/17/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

      Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relations and Communications, succeeding Jamie Webb, Director of Communications and Investor Relations, who recently announced her retirement. Jamie will remain in her role into August to support a smooth and effective transition. "We are excited to welcome Mike to the Harrow Family. His wealth of experience in investor relations and strategic communications will be a tremendous asset as we pursue our objective of becoming the leading U.S. ophthalmic pharmaceutical company," said Mark L. Baum, Chief Executive Officer of Harrow. "I a

      6/18/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    SEC Filings

    See more
    • Harrow Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - HARROW, INC. (0001360214) (Filer)

      7/17/25 7:16:10 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Harrow Inc.

      S-8 - HARROW, INC. (0001360214) (Filer)

      6/20/25 7:22:12 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - HARROW, INC. (0001360214) (Filer)

      6/20/25 6:01:59 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Harrow with a new price target

      Cantor Fitzgerald initiated coverage of Harrow with a rating of Overweight and set a new price target of $76.00

      7/11/25 8:12:59 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Harrow with a new price target

      BTIG Research initiated coverage of Harrow with a rating of Buy and set a new price target of $62.00

      6/12/25 7:54:43 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • William Blair initiated coverage on Harrow

      William Blair initiated coverage of Harrow with a rating of Outperform

      6/10/25 8:09:06 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Opaleye Management Inc. bought $199,400 worth of shares (20,000 units at $9.97) (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      4/25/24 5:19:24 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Opaleye Management Inc. bought $204,640 worth of shares (20,000 units at $10.23) (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      4/24/24 4:40:20 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Opaleye Management Inc. bought $310,390 worth of shares (29,400 units at $10.56) (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      4/19/24 6:24:32 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Baum Mark L covered exercise/tax liability with 313,338 shares and exercised 600,000 shares at a strike of $7.87, increasing direct ownership by 11% to 2,886,124 units (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      7/23/25 9:10:48 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF FINANCIAL OFFICER Boll Andrew R.

      4 - HARROW, INC. (0001360214) (Issuer)

      7/1/25 4:45:26 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Baum Mark L

      4 - HARROW, INC. (0001360214) (Issuer)

      7/1/25 4:45:24 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Leadership Updates

    Live Leadership Updates

    See more
    • Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

      Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relations and Communications, succeeding Jamie Webb, Director of Communications and Investor Relations, who recently announced her retirement. Jamie will remain in her role into August to support a smooth and effective transition. "We are excited to welcome Mike to the Harrow Family. His wealth of experience in investor relations and strategic communications will be a tremendous asset as we pursue our objective of becoming the leading U.S. ophthalmic pharmaceutical company," said Mark L. Baum, Chief Executive Officer of Harrow. "I a

      6/18/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

      Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophthalmic indications. Dr. Shojaei most recently served as CSO and Executive Vice President of Clinical Development at AsclepiX Therapeutics, where he spearheaded the development of innovative therapies for neovascular retinal disorders. P

      1/7/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial

      Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow's rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow's commitment to enhancing its leadership structure to support the Company's continued growth. John Saharek, Harrow's Chief Commercial Officer and Chief Executive Officer of ImprimisRx, will continue to oversee Harrow's commercial business, focusing on the day-to-day management of Harrow's market‑leading compounded division. DiPasquale

      5/13/24 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Harrow Inc.

      SC 13G/A - HARROW, INC. (0001360214) (Subject)

      12/5/24 7:08:52 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Harrow Inc.

      SC 13G/A - HARROW, INC. (0001360214) (Subject)

      10/8/24 6:41:41 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Harrow Inc. (Amendment)

      SC 13G/A - HARROW, INC. (0001360214) (Subject)

      2/13/24 5:25:53 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Financials

    Live finance-specific insights

    See more
    • Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

      Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW), today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05%. BYQLOVI was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-operative inflammation and pain following ocular surgery and is the first new ophthalmic steroid in its class in over 15 years. Harrow expects BYQLOVI to be available in the fourth quarter of 2025. This press release features multimedia. View the full release here: https://www.busin

      6/9/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Announces First-Quarter 2025 Financial Results

      First-Quarter 2025 and Recent Selected Highlights: Revenues of $47.8 million, a 38% increase over $34.6 million recorded in prior-year period VEVYE revenues increased to $21.5 million, a 35% increase from $16.0 million in the fourth quarter 2024 Cash flow from operations reached a record high of $19.7 million GAAP net loss of $(17.8) million Adjusted EBITDA of $(2.0) million Cash and cash equivalents of $66.7 million as of March 31, 2025 VEVYE® Access for All launch in mid-March is accelerating market share capture and revenue growth Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2025. Th

      5/8/25 4:01:00 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

      Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on May 9, 2025 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, after the market close. The Company will also post its first quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Friday, May 9, 2025, to discuss the results and provide a business update. Conference Call Information Participants can access the live conference call via webcast on th

      5/5/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care